Enlivex Therapeutics Past Earnings Performance
Past criteria checks 0/6
Enlivex Therapeutics's earnings have been declining at an average annual rate of -26.7%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-26.7%
Earnings growth rate
-9.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -78.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Enlivex Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -22 | 5 | 14 |
| 31 Mar 24 | 0 | -26 | 6 | 17 |
| 31 Dec 23 | 0 | -29 | 6 | 19 |
| 30 Sep 23 | 0 | -27 | 7 | 20 |
| 30 Jun 23 | 0 | -27 | 7 | 20 |
| 31 Mar 23 | 0 | -30 | 7 | 19 |
| 31 Dec 22 | 0 | -31 | 7 | 19 |
| 30 Sep 22 | 0 | -29 | 8 | 18 |
| 30 Jun 22 | 0 | -26 | 7 | 17 |
| 31 Mar 22 | 0 | -19 | 7 | 15 |
| 31 Dec 21 | 0 | -14 | 6 | 13 |
| 30 Sep 21 | 0 | -16 | 5 | 10 |
| 30 Jun 21 | 0 | -14 | 5 | 9 |
| 31 Mar 21 | 0 | -14 | 4 | 7 |
| 31 Dec 20 | 0 | -12 | 4 | 6 |
| 30 Sep 20 | 0 | -9 | 4 | 5 |
| 30 Jun 20 | 0 | -9 | 3 | 6 |
| 31 Mar 20 | 0 | -8 | 3 | 5 |
| 31 Dec 19 | 0 | -10 | 3 | 6 |
| 30 Sep 19 | 0 | -9 | 2 | 5 |
| 30 Jun 19 | 0 | -7 | 2 | 5 |
| 31 Mar 19 | 0 | -7 | 2 | 5 |
| 31 Dec 18 | 0 | -5 | 1 | 4 |
| 30 Sep 18 | 0 | -4 | 1 | 3 |
| 31 Dec 17 | 0 | -3 | 0 | 2 |
Quality Earnings: 1BT is currently unprofitable.
Growing Profit Margin: 1BT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1BT is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.
Accelerating Growth: Unable to compare 1BT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1BT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 1BT has a negative Return on Equity (-78.05%), as it is currently unprofitable.